Clinical trials: Gastric
Gastroesophageal Reflux Disease, Reflux, Gastroesophageal
Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.
Current treatment for gastroesophageal reflux disease(GERD)confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric acid suppression.
- Trial name
- NCT00551473
- Testing
- Lavoltidine
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive…
- Trial name
- NETTER-3 (NCT06784752)
- Testing
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Where
- 67 sites in United States, Canada and 10 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Esophagitis, Reflux
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis.
- Trial name
- NCT00282555
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- 17 sites in Canada
- Volunteers
- 450 people
- Sponsor
- STEBA France
Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms
Gastrointestinal Anastomosis Using MonoPlus® Suture
The primary aim of this study is to collect clinical data on the performance of MonoPlus® suture applied in routine clinical practice.
- Conditions
- Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms, Digestive System Neoplasm, Stomach Tumor
- Trial name
- GASTROMO (NCT04811833)
- Where
- 2 sites in Spain
- Sponsor
- Aesculap AG
Obesity & Overweight
Gastric On in Obesity Management: Evaluation of the Safety and Efficacy of the 6-Month Gastric Balloon (Prospective)
The goal of this clinical study is to learn whether the GastricOn 6-Month Gastric Balloon helps adults with obesity lose weight, and how safe it is.
- Trial name
- GastricOn (NCT07869758)
- Testing
- GastricOn intragastric balloon
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Rigicon, Inc.
Gastric Ulcer
Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer
A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer
- Trial name
- NCT07730138
- Testing
- DWP14012 40mg (Fexuprazan), Lansoprazole 30mg
- Where
- 2 sites in Indonesia, South Korea
- Volunteers
- 384 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
HER2-positive Breast Cancer, Cervical Cancer
Tucatinib Continuation Study
The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment.
- Conditions
- HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer
- Trial name
- NCT07768358
- Testing
- tucatinib
- Volunteers
- 175 people
- Sponsor
- Pfizer
Gastric Cancer
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line…
- Trial name
- NCT01924533
- Testing
- Olaparib, Paclitaxel
- Where
- 57 sites in China, Japan and 2 more
- Volunteers
- 525 people
- Sponsor
- AstraZeneca
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally…
- Trial name
- NCT06116136
- Testing
- S095029, pembrolizumab 200 mg (KEYTRUDA ®)
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 48 people
- Sponsor
- Servier Bio-Innovation LLC
HNSCC, ESCC
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07182149
- Testing
- NRM-823
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Normunity AccelCo, Inc.
Gastro-intestinal Tolerance
GI Tolerance and Acceptability of a New Thickener
The current study is designed to evaluate the gastrointestinal tolerance and acceptability of a new thickener for dysphagia patients.
- Trial name
- NCT04104815
- Testing
- Experimental Thickener
- Sponsor
- Abbott Nutrition
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
- Trial name
- NCT02625623
- Testing
- Avelumab, Irinotecan, Paclitaxel
- Where
- 75 sites in United States, Australia and 8 more
- Volunteers
- 371 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Nocturnal Symptoms of GERD, Sleep Disorders in GERD
QUality of Sleep Improvement With Evening Topical Therapy for Non-Erosive Gastroesophageal Reflux Disease (The QUIET Trial)
The goal of this randomized, double-blind, single-center clinical trial is to learn if medical devices work to decrease nocturnal symptoms of GERD gastroesophageal reflux disease in adults' patients and improve sleeping time…
- Conditions
- Nocturnal Symptoms of GERD, Sleep Disorders in GERD, GERD (Gastroesophageal Reflux Disease), Non-Erosive Gastro-Esophageal Reflux Disease
- Trial name
- QUIET (NCT07700342)
- Where
- 2 sites in Poland
- Volunteers
- 50 people
- Sponsor
- Cellmedis
Obesity, Roux-en-Y Gastric Bypass
A Post-market Observational Study With the easyEndoTM Universal Linear Cutting Stapler in Standard Laparoscopic and Robot-assisted Laparoscopic Roux-en-Y Gastric Bypass (RYGB) Surgery
The primary purpose of this observational registry is to evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical when used to create anastomoses during standard and robot-assisted…
- Trial name
- SIRIUS (NCT04543526)
- Testing
- easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
- Where
- 2 sites in Belgium
- Sponsor
- Duomed
Esophagitis, Reflux
To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis
The purpose of this study is to evaluate the efficacy and safety of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium 10mg in patients with erosive esophagitis of Grade A to D as defined by the LA classification…
- Trial name
- NCT02463643
- Testing
- Z-215 10mg, Z-215 20mg, Rabeprazole Sodium
- Where
- Japan
- Volunteers
- 503 people
- Sponsor
- Zeria Pharmaceutical
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Gastro-Intestinal Disorder, Barrett Esophagus
Clinical Utility Evidence for TissueCypher®
Cernostics has developed a new diagnostic test, and this study will measure how gastroenterologists and foregut surgeons make diagnostic and treatment decisions when presented with different information in the context of…
- Trial name
- NCT05200325
- Testing
- Educational materials for TissueCypher
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Qure Healthcare, LLC
Pulmonary Disease, Chronic Obstructive
GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
This 2-part study will be carried out on healthy elderly subjects to evaluate relative bioavailability of danirixin formulations.
- Trial name
- NCT03457727
- Testing
- Danirixin, Omeprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gastric Cancer, Non-small Cell Lung Cancer
Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers
Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist.
- Conditions
- Gastric Cancer, Non-small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05800418
- Testing
- Ramucirumab Injection, Ramucirumab Injection [Cyramza]
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.